New hope for hard-to-treat blood cancers: experimental drug enters human testing

NCT ID NCT06708897

First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 29 times

Summary

This early-phase study tests a new drug called ZE50-0134 in about 66 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain low-grade lymphomas that have returned or not responded to prior therapies. The main goals are to check the drug's safety and how well it works. Participants must have already tried at least two other treatments, including a BTK inhibitor and venetoclax (or declined it).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLL (CHRONIC LYMPHOCYTIC LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Norton Cancer Institute, St. Matthews Campus

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45221, United States

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

Conditions

Explore the condition pages connected to this study.